2 results
Approved WMOCompleted
The primary aim is to investigate whether six weeks augmentation with clonidine of the antipsychotic treatment will reduce positive and negative symptomatology of treatment resistant schizophrenia patients. Important secondary goals of this project…
Approved WMORecruiting
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…